MSD launches Vaxneuvance: Protecting all ages against pneumococcal diseaseApril 26, 2024
Vaxneuvance offers protection against 15 serotypes of Streptococcus pneumoniae.
Today marks a significant milestone for MSD in the fight against pneumococcal disease with the introduction of Vaxneuvance, a new generation 15-valent pneumococcal conjugate vaccine.
This vaccine offers protection against 15 serotypes of Streptococcus pneumoniae, providing active immunization protection for the prevention of pneumococcal disease caused by Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, 22F, 23F and 33F in individuals 6 weeks of age and older. In Malaysia, the prevalence of pneumonia in children under 5 years of age is between 28-39%, which poses a significant threat to the children. Based on the most recent statistics from the Department of Statistics Malaysia (DOSM), it ranks as the second leading cause of death, accounting for 13.3% across all age groups. Specifically, for children aged 0-14 years, it is the number one cause of death, constituting 4% of fatalities in this age group. Additionally, pneumococcal disease also contributes up to 21.7% of the community-acquired pneumonia cases in Malaysia. Streptococcus pneumoniae is the most common bacterial pathogen for community-acquired pneumonia. Invasive Pneumococcal disease (IPD) is an infection caused by the bacterium Streptococcus pneumoniae, or pneumococcus. Some examples of IPD are bacteremia (an infection in the blood) and meningitis (an infection of the coverings of the brain and spinal cord), which can also result in long-term neurological complications. The pneumococcal vaccine has been introduced in the National Immunisation Programme (NIP) for children since January 2020. The newly developed vaccine is anticipated to provide broader coverage and potential advantages. With protection against risk-causing serotypes, it has the potential to further reduce the overall burden of the disease by addressing the evolving epidemiology of Streptococcus pneumoniae. “It has been recognized that serotype-specific immune responses may decrease further as more serotypes are added into a new higher valency vaccine. Maintaining robust immune responses to current PCV serotypes is crucial, while expanding coverage and enhancing immunogenicity for specific serotypes, like serotype 3, is also important. Serotype-3 is associated with a significant disease burden in the adult population in Malaysia, causing the highest number of cases of invasive pneumococcal diseases (19.8%) and the second-highest in non-invasive pneumococcal disease (11.11%), it remains a concern among adults. Improving immunogenicity against serotype-3 is a key goal that PCV15 has achieved“, added Associate Professor Petrick Periyasamy, infectious disease specialist. Introducing the latest vaccine represents a significant step forward in efforts to reduce the burden of pneumococcal disease and its devastating impact on individuals, families, and communities, offering hope for improved protection for children and older adults in Malaysia. The vaccine will be accessible at clinics and hospitals across the nation starting from April 2024. EXPLORE FURTHER |
|
|
Taking quality lumbar support to new heightsWorld's first cordless massage chair debuts on the peak of Mount Kinabalu
|
|
DKSH Malaysia - Botrem partner to revolutionize skin rehabilitationTargeted solutions for persistent allergies
|
|
Duopharma Biotech - Owen Mumford partners to distribute medical devicesDiabetes and eye care products to be distributed as part of the agreement
|
|
Columbia Asia sets foot in Bukit JalilSeven-story hospital offering 96 ward beds and multi-specialties
|
|
Sunway Medical Centre Velocity introduces robotic surgery serviceA minimally invasive alternative to laparoscopic surgery
|
|
Danone Malaysia - the first food company to be certified B CorporationAdvocate of Iron Deficiency Anaemia (IDA) among Malaysian children
|
|
Preserving female cancer patients' fertility via cryopreservationIdeal for girls pre-puberty and women in reproductive age
|
|
Monurol (Fosfomycin Trometamol) receives DCA approval for transrectal prostate biopsy in adult menNew indication of perioperative antibiotic prophylaxis
|
|
Roche-MUIS announce funding for breast cancer patientsAccess to neoadjuvant therapy for HER-2 positive breast cancer patients
|
|
5-year-old Khaivan gains hearing ability through cochlear implant surgeryAudiolab's hearing solutions bring hope to those with hearing loss
|
|
Mahkota Medical Centre earns CCPC accreditation for breast cancerRM250 million investment towards healthcare transformation
|
|
UMW Toyota's generous donation bolsters cancer society's vital servicesExpanding cancer care reach and access
|
